This trial is evaluating whether Bevacizumab will improve 2 primary outcomes and 1 secondary outcome in patients with Glioblastoma. Measurement will happen over the course of 1 month ongoing.
This trial requires 25 total participants across 1 different treatment group
This trial involves a single treatment. Bevacizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"1,600 babies in the United States develop glioblastoma each year. The 2-year survival of 12% is below the survival rate of 20%-40% in other countries. As glioblastoma tends to develop early, prompt intervention in children at risk is required. Given the shortcomings of the current screening protocol, the incorporation of an adjuvant protocol for all children at risk will be studied, with a view to making the current protocol more inclusive." - Anonymous Online Contributor
"If the glioblastoma was diagnosed as a young child, the survival rate is significantly better (log-rank, p < 0.0001). Younger patients may have a high probability of survival." - Anonymous Online Contributor
"Treatment for glioblastoma is an extremely variable process. Surgical resection is the standard form of treatment for high-grade gliomas with a median survival of 2-3 months from the time of surgery; however, radiotherapy is rarely administered. Atypical presentation and recurrence patterns are reasons why surgical resection is not routinely sought in all patients. Radiotherapy used as adjuvant therapy after surgery is very variable. Temozolomide and temozolomide monotherapy is the standard of care in the treatment of glioblastoma despite its limited impact on survival." - Anonymous Online Contributor
"The authors' research confirmed the presence of four signs in GBM patients, including nausea/vomiting, headache, constipation/stomach ache, and neurological symptoms. The authors hypothesize that tumor-associated neurological symptoms arise from the blood-brain barrier disruption caused by the tumor." - Anonymous Online Contributor
"This rare and rapidly fatal tumour is characterised by an aberrant accumulation of cells that give rise to a heterogeneous cellular 'population', including stem cells and other cell populations involved in tumour development and progression including glioma stem cells and cancer stem cells. Glioblastoma, however, has been found in younger children than in adults with a higher percentage of anaplastic and lower numbers of non-anaplastic malignant glioma. An examination of histological variants of glioblastoma in children and adults is needed to better understand these variants and thereby improve clinical treatments of children with glioblastoma to achieve improved survival rates." - Anonymous Online Contributor
"The study provides evidence of four independent pathways leading to glioblastoma: genetic mutations, altered metabolism, environmental insults and other tumor suppressor events. The current therapeutic paradigm focuses on the cytotoxic function of temozolomide, which was proven to be insufficient when applied as single agent. Recent findings confirms the current hypothesis that resistance to temozolomide develops, most likely through up-regulation of the proteasome system, which reduces the effect of temozolomide. For this effect, additional targeting agents are warranted." - Anonymous Online Contributor
"The data indicate that bevacizumab does not increase the rate of grade 3/4 adverse events. Side effects do occur, however, which often resolves at the end of or after cycle 2." - Anonymous Online Contributor
"As far as we know, there is no existing treatment combination in the treatment setting yet for people with glioblastoma. There are several possible drug combinations that could be explored for this condition in the absence of clinical data: targeting EGFR or PDCD and targeting the PI3K/Akt axis. Since we know of the potential benefit of Bevacizumab in other tumor types, clinicians should consider whether and in what context it could be used as part of their treatment program." - Anonymous Online Contributor
"Most patients with GBM receive adjuvant radiation after treatment with a first-line chemotherapy and chemotherapy boost. These data suggest that GBM is associated with an excellent clinical course and prolonged survival compared with patients who do not receive adjuvant radiation therapy." - Anonymous Online Contributor
"Bevacizumab is effective in achieving an improvement in survival rate in patients with recurrent glioblastoma. However, the benefit is most pronounced in those cases in which the number of surgeries equals one-half or more of the number of treatment cycles. For future treatment of these patients bevacizumab should be used with caution." - Anonymous Online Contributor
"The effect of bevacizumab on progression free survival of recurrent GBM is similar to that seen in the trials conducted in advanced cancers and is likely to result in better quality of life for patients. Further randomized controlled trials of bevacizumab are warranted in this setting." - Anonymous Online Contributor
"The average age was 64.5 years, but a significant proportion of patients were younger and older; therefore, the age distribution should be considered when choosing the optimum treatment strategy for patients with glioblastoma." - Anonymous Online Contributor